These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 2836547)

  • 21. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
    Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
    Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs.
    Garg R; Latimer L; Gomis S; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2019 Feb; 162():54-60. PubMed ID: 30550799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional and structural basis of human parainfluenza virus type 3 neutralization with human monoclonal antibodies.
    Suryadevara N; Otrelo-Cardoso AR; Kose N; Hu YX; Binshtein E; Wolters RM; Greninger AL; Handal LS; Carnahan RH; Moscona A; Jardetzky TS; Crowe JE
    Nat Microbiol; 2024 Aug; 9(8):2128-2143. PubMed ID: 38858594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge.
    Greer CE; Zhou F; Legg HS; Tang Z; Perri S; Sloan BA; Megede JZ; Uematsu Y; Vajdy M; Polo JM
    Vaccine; 2007 Jan; 25(3):481-9. PubMed ID: 17052811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquisition of serum antibodies to specific viral glycoproteins of parainfluenza virus 3 in children.
    Kasel JA; Frank AL; Keitel WA; Taber LH; Glezen WP
    J Virol; 1984 Dec; 52(3):828-32. PubMed ID: 6092715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in bovine parainfluenza 3 virus variants studied by monoclonal antibodies against viral glycoproteins.
    Shibuta H; Suzu S; Shioda T
    Virology; 1986 Dec; 155(2):688-96. PubMed ID: 3024407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats.
    Ambrose MW; Wyde PR; Ewasyshyn M; Bonneau AM; Caplan B; Meyer HL; Klein M
    Vaccine; 1991 Jul; 9(7):505-11. PubMed ID: 1654680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective effect of monoclonal antibodies to Newcastle disease virus in passive immunization.
    Umino Y; Kohama T; Sato TA; Sugiura A
    J Gen Virol; 1990 May; 71 ( Pt 5)():1199-203. PubMed ID: 2345369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microencapsulated human parainfluenza virus induces a protective immune response.
    Ray R; Novak M; Duncan JD; Matsuoka Y; Compans RW
    J Infect Dis; 1993 Mar; 167(3):752-5. PubMed ID: 8382726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection of cotton rats by immunization with the human parainfluenza virus type 3 fusion (F) glycoprotein expressed on the surface of insect cells infected with a recombinant baculovirus.
    Hall SL; Murphy BR; van Wyke Coelingh KL
    Vaccine; 1991 Sep; 9(9):659-67. PubMed ID: 1659054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolation and characterization of monoclonal antibodies to human parainfluenza virus type 4 and their use in revealing antigenic relation between subtypes 4A and 4B.
    Komada H; Tsurudome M; Ueda M; Nishio M; Bando H; Ito Y
    Virology; 1989 Jul; 171(1):28-37. PubMed ID: 2472703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies.
    Coelingh KJ; Winter CC; Murphy BR; Rice JM; Kimball PC; Olmsted RA; Collins PL
    J Virol; 1986 Oct; 60(1):90-6. PubMed ID: 2427750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys.
    Tang RS; Mahmood K; Macphail M; Guzzetta JM; Haller AA; Liu H; Kaur J; Lawlor HA; Stillman EA; Schickli JH; Fouchier RA; Osterhaus AD; Spaete RR
    Vaccine; 2005 Feb; 23(14):1657-67. PubMed ID: 15705469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3.
    Homa FL; Brideau RJ; Lehman DJ; Thomsen DR; Olmsted RA; Wathen MW
    J Gen Virol; 1993 Sep; 74 ( Pt 9)():1995-9. PubMed ID: 8397289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection.
    Spriggs MK; Collins PL; Tierney E; London WT; Murphy BR
    J Virol; 1988 Apr; 62(4):1293-6. PubMed ID: 2831389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.
    Greer CE; Zhou F; Goodsell A; Legg HS; Tang Z; zur Megede J; Uematsu Y; Polo JM; Vajdy M
    Scand J Immunol; 2007 Dec; 66(6):645-53. PubMed ID: 17944814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
    Durbin AP; Cho CJ; Elkins WR; Wyatt LS; Moss B; Murphy BR
    J Infect Dis; 1999 Jun; 179(6):1345-51. PubMed ID: 10228053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
    Tao T; Durbin AP; Whitehead SS; Davoodi F; Collins PL; Murphy BR
    J Virol; 1998 Apr; 72(4):2955-61. PubMed ID: 9525616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative analysis of the immunostimulatory properties of different adjuvants on the immunogenicity of a prototype parainfluenza virus type 3 subunit vaccine.
    Ewasyshyn M; Caplan B; Bonneau AM; Scollard N; Graham S; Usman S; Klein M
    Vaccine; 1992; 10(6):412-20. PubMed ID: 1317984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serological diagnosis of parainfluenza virus infections by enzyme immunoassay with special emphasis on purity of viral antigens.
    Julkunen I
    J Med Virol; 1984; 14(2):177-87. PubMed ID: 6092530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.